Organization: Health Canada
Year: 2023
Month: January
Request Number: A-2022-000999
Request Summary: The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the Good Clinical Practices (GCP) inspection of Phase 2 for the Methylenedioxymethamphetamine (MDMA) trial by the Multidisciplinary Association for Psychedelic Studies facility on Stevens Creek Blvd, San Jose, California, USA, starting around 6 June 2022. Control Number 240514.
Disposition: Disclosed in part
Number of pages: 11